Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation

Transplantation

Volumn 74, Issue 8, 2002, Pages 1198-1200

  Kobbe, Guido ^a   Germing, Ulrich ^a   Aivado, Manuel ^a   Zohren, Fabian ^a   Schubert, Dominik ^a   Strupp, Corinna ^a   Pape, Hildegard ^a   Tenderich, Gero ^a   Körfer, Reiner ^a   Storb, Rainer ^a   Haas, Rainer ^a   Schneider, Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CD3 ANTIGEN; CYCLOSPORIN A; CYTARABINE; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CANCER CHEMOTHERAPY; CASE REPORT; DISEASE COURSE; ERYTHROCYTE APLASIA; GRAFT VERSUS HOST REACTION; HEART FUNCTION; HEART TRANSPLANTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MALE; MYELODYSPLASTIC SYNDROME; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; VIRUS INFECTION; WHOLE BODY RADIATION;

EID: 0037184331     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200210270-00027     Document Type: Article

References (10)

1. Flattery MP, Incidence and treatment of cancer in transplant recipients, J Transpl Coord 1998; 8(2): 105.
2. Penn I. Posttransplant malignancies, Transplant Proc 1999; 31: 1260.
3. Huebener G, Karthaus M, Pethig K, et al. Myelodysplastic syndrome and acute myelogenous leukemia secondary to heart transplantation. Transplantation 2000; 70(4): 688.
4. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756.
5. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390.
6. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68(4): 480.
7. Kwong YL, Au WY, Liang RH. Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: Association with -7/7q. Cancer Genet Cytogenet 1998; 104(2): 94.
8. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposal for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 2000; 24: 983.
9. Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible non-myeloablative hematopoietic stem cell transplantation. Blood 2001; 98: 1687.
10. Veelken H, Wäsch R, Behringer D, et al. Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning. Bone Marrow Transplant 2000; 26(8): 911.